Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05617755 · ClinicalTrials.gov registry record · Phase 1
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
A Phase 1 study of Ovarian Neoplasms and Peritoneal Neoplasms, sponsored by Arsenal Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 8
- Study locations
NCT05617755 is a Phase 1 study of Ovarian Neoplasms and Peritoneal Neoplasms that is active but no longer recruiting, run by Arsenal Biosciences. The registered enrollment target is 19 participants, below the 367-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (95% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT05617755, a Phase 1 study of Ovarian Neoplasms and Peritoneal Neoplasms, is active but no longer recruiting, sponsored by Arsenal Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.
Conditions Studied
Interventions
- BIOLOGICAL AB-1015
Study Locations (8)
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Colorado
- U of Colorado Cancer Center - Anschutz Medical Campus - Aurora
Iowa
- U of Iowa Health Care - Iowa City
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Texas
- MD Anderson Cancer Center - Houston
Washington
- U of Washington - Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-11-29 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05617755
The ClinicalTrials.gov registry entry for NCT05617755 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 367-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (95% lower). The listed sponsor is Arsenal Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Ovarian Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which AB-1015 is the first listed.
NCT05617755 reports 8 study locations spanning 7 distinct geographic areas - top geographies include New York, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05617755 about?
NCT05617755 is a clinical study titled "AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer". This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each bac...
What is the current status of trial NCT05617755?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2022-11-29. Estimated completion is 2027-02.
What conditions does trial NCT05617755 study?
This clinical trial studies the following conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Recurrence, Carcinoma, Ovarian Epithelial.
What interventions are being tested in trial NCT05617755?
The interventions under investigation include: AB-1015 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05617755?
This trial is sponsored by Arsenal Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05617755 being conducted?
This trial has 8 study locations across California, Colorado, Iowa, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
-
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
RECRUITING · Phase 1
-
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.